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Edited by Robert BaroukiAbstract IGF-I is degraded within the endosomal apparatus as
a consequence of receptor-mediated endocytosis. However, the
nature of the responsible protease and the position of the
cleavage sites in the IGF-I molecule remain undeﬁned. In vitro
proteolysis of IGF-I using an endosomal lysate required an acidic
pH and was sensitive to CA074, an inhibitor of the cathepsin B
enzyme. By nondenaturing immunoprecipitation, the acidic
IGF-I-degrading activity was attributed to the luminal species
of endosomal cathepsin B with apparent molecular masses of
32- and 28-kDa. The cathepsin B precursor, procathepsin B,
was processed in vitro within isolated endosomes at pH 5 or at
7 in the presence of ATP, the substrate of the vacuolar H+-ATP-
ase. The rate of IGF-I hydrolysis using an endosomal lysate or
pure cathepsin B was found to be optimal at pH 5–6 and moder-
ate at pH 4 and 7. Competition studies revealed that EGF and
IGF-I share a common binding site on the cathepsin B enzyme,
with native IGF-I displaying the lowest aﬃnity for the protease
(IC50  1.5 lM). Hydrolysates of IGF-I generated at low pH by
endosomal IGF-I-degrading activity and analyzed by reverse-
phase HPLC and mass spectrometry revealed cleavage sites at
Lys68-Ser69, Ala67-Lys68, Pro66-Ala67 and Lys65-Pro66 within
the C-terminal D-domain of IGF-I. Treatment of human HepG2
hepatoma cells with the cathepsin B proinhibitor CA074-Me
reduced, in vivo, the intracellular degradation of internalized
[125I]IGF-I and, in vitro, the degradation of exogenous
[125I]IGF-I incubated with the cell-lysates at pH 5. Inhibitors
of cathepsin B and pro-cathepsin B processing, which abolish
endosomal proteolysis of IGF-I and alter tumor cell growth
and IGF-I receptor signalling, merit investigation as antimeta-
static drugs.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Insulin-like growth factor I (IGF-I) is a 70-amino acid single
polypeptide chain that mediates somatic growth by binding to
the IGF-I receptor [1]. It has a high sequence similarity with
insulin-like growth factor-II (IGF-II) and the A and B chains
of human insulin [2]. IGF-I binding initiates the migration of
IGF-I receptors to clathrin-coated pits and the subsequent
formation of early endosomes containing internalized but still
active receptors [3,4]. Cellular compartmentalization by IGF-I-
induced IGF-I receptor internalization is required for cell
signalling via the Shc/MAP kinase pathway, but not the
IRS-1 pathway [4]. The IGF-I/IGF-I receptor complex
ultimately becomes dissociated in the acidic endosomal
environment where IGF-I proteolysis takes place [3,5].
Endosomal proteolysis of IGF-I is thought to be required
for cellular responses to IGF-I and IGF-I receptor recycling
to the cell surface [5].
Endosomal IGF-I degrading activity has been shown to be
strongly inhibited by cysteine protease inhibitors and easily
extracted from endocytic vesicles of rat liver parenchyma, or
carcinoma H-59 and MCF-7 cells [5]. However, the identity
of the responsible proteinase remained unknown, and thus
far no study has been directed towards identifying the IGF-I
degradation products and the proteolytic cleavage sites. Eluci-
dation of these sites in the human IGF-I molecule is essential
for a better understanding of the substrate recognition and
cleavage site speciﬁcity of the endosomal IGF-I degrading
enzyme and would facilitate the design of inhibitors and prote-
ase-resistant IGF-I analogues.
Recently, we have identiﬁed the structural domains of insu-
lin responsible for binding to and degradation by endosomal
cathepsin D [6,7]. The aromatic locus PheB24-PheB25-TyrB26
at the C-terminal region of the insulin B chain was deﬁned
as critical to the high-aﬃnity interaction of insulin with
cathepsin D. The insulin B chain is homologous to the
amino-terminal 29-residue region of human IGF-I [8]. IGF-I
contains an additional connecting C-domain, which joins its
B domain to a region corresponding to the A chain of insulin,
and an extension at the C-terminus known as the D-domain
[2]. In the present study, we show that proteolysis of IGF-I
was strongly inhibited, both in vivo and in vitro, in human
HepG2 hepatoma cells pretreated with the cathepsin B proin-
hibitor CA074-Me, and in vitro, using hepatic endosomes
incubated with the cathepsin B inhibitor CA074. Using highly
puriﬁed rat endosomes, the degradation products of nativeblished by Elsevier B.V. All rights reserved.
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tides determined by mass spectrometry. The data demonstrate
that the cysteine protease cathepsin B is responsible for the
endosomal processing of IGF-I by inducing proteolytic cleav-
ages that yield C-terminal truncated forms of IGF-I.2. Materials and methods
2.1. Peptides, ligand radioiodination, antibodies, protein determination
and materials
Recombinant human IGF-I and insulin were purchased from Sigma
and Preprotech Inc. Mouse EGF was purchased from Collaborative
Research. Bovine cathepsin B (EC 3.4.22.1; 10 U/mg) and bovine
cathepsin D (EC 3.4.23.5; 5 U/mg) were purchased from Sigma.
IGF-I was radioiodinated by the lactoperoxidase method to speciﬁc
activities of 350–500 Ci/mmol and puriﬁed by gel ﬁltration on Sepha-
dex G-50 [5]. Rabbit anti-mouse cathepsin D R291, rabbit anti-rat
cathepsin B 7183, rabbit anti-rat cathepsin L R958 and rabbit anti-
rat cathepsin B propeptide 1149 were obtained from Dr. J.S. Mort
(Shriners Hospital for Crippled Children, Montreal, Quebec) and used
as described previously [7,9,10]. Sheep anti-human cathepsin B PC049
was purchased from The Binding Site. Mouse monoclonal antibody
9B12 directed to the human insulin-degrading enzyme [11] was ob-
tained from Dr. R.A. Roth (Stanford University, Stanford, CA).
HRP-conjugated goat anti-rabbit IgG was from Bio-Rad. The protein
content of isolated fractions was determined by the method of Lowry
et al. [12]. Nitrocellulose membranes and Enhanced ChemiLumines-
cence (ECL) detection kit were from Amersham. Protein G-Sepharose
was from Pharmacia. Pepstatin-A, E-64, PMSF and baﬁlomycin A1
were from Sigma. CA074 and its methyl ester form, CA074-Me, were
purchased from Peptides International. HPLC grade acetonitrile and
triﬂuoroacetic acid (TFA) were obtained from Baker Chemical Co.
All other chemicals were obtained from commercial sources and were
of reagent grade.2.2. Cell culture
Human HepG2 cells were grown in Dulbeccos modiﬁed Eagles
medium (DMEM) supplemented with 10% (v/v) fetal bovine serum
and 1% penicillin/streptomycin in an atmosphere of 95% air/5%
CO2 as described previously [13]. CA074-Me, a membrane perme-
able analog of CA074 [14], was dissolved in DMSO (stock concen-
tration of 1 mM) resulting in a ﬁnal DMSO concentration of 0.1%
(v/v) in the medium. Control cells received 0.1% DMSO only.
HepG2 cells were incubated in the presence of 1 lM CA074-Me
60 min before addition of radiolabeled IGF-I or preparation of cell
lysates.2.3. IGF-I internalization and degradation in hepatoma cells
A modiﬁcation of the procedure of Zapf et al. [15] was followed.
HepG2 cells were grown to subconﬂuency on 55 mm culture dishes,
rinsed three times in HBS buﬀer (50 mM HEPES, pH 7.5, 150 mM
NaCl) and incubated for various times at 37 C with 1 ml of HBS con-
taining 17000 cpm [125I]IGF-I. At the indicated times, cells were placed
on ice and washed three times with ice-cold HBS. To remove the sur-
face-bound ligand, cells were acid washed three times for 5 min at 4 C
in the presence of 1 ml 50 mM citrate–phosphate, pH 3.5, 150 mM
NaCl and the acid-washes were counted in a Packard c-counter. The
integrity of radiolabeled IGF-I remaining cell-associated was assayed
by adding 2 ml of ice-cold 6% trichloroacetic acid (TCA). The samples
were then centrifuged at 10000 · g for 20 min at 4 C, and the super-
natants and pellets were evaluated for their radioactive content.
Proteolysis of [125I]IGF-I was also measured using cell lysates de-
rived from HepG2 cells which had been pretreated for 60 min with
or without 1 lM CA074-Me as described previously [5]. Cells were
washed three times with HBS, scraped and lysed in HBS buﬀer con-
taining 1% Triton X-100 and 0.5% deoxycholate. The lysates were clar-
iﬁed by centrifugation for 60 min at 60000 · g. The clariﬁed lysates
were then incubated for various times at 37 C with 10000 cpm
[125I]IGF-I in 200 ll of 300 mM citrate–phosphate, pH 5, and the
integrity of [125I]IGF-I was assessed by reducing Tris–Tricine gels.2.4. Animals and liver subcellular fractionation
Male Sprague-Dawley rats, body weight 180–200 g, were obtained
from Charles River France (St. Aubin Les Elbeufs, France) and were
fasted for 18 h prior to sacriﬁce. All in vivo procedures were approved
by the institutional committee for use and care of experimental
animals.
Subcellular fractionation was performed using established proce-
dures [7,9–11]. The endosomal (EN) fraction was isolated by discontin-
uous sucrose gradient centrifugation and collected at the 0.25–1.0 M
sucrose interface [7,9–11]. The soluble endosomal extract (ENs) was
isolated from the EN fraction by freeze/thawing in 5 mM Na-phos-
phate pH 7.4, and disrupted in the same hypotonic medium using a
small Dounce homogenizer (15 strokes with Type A pestle) followed
by centrifugation at 150000 · g for 60 min as previously described
[7,9–11].
For some experiments, freshly isolated endosomes were suspended
at 0.5 mg/ml in 0.15 M KCl, 5 mM MgCl2 and 25 mM citrate–phos-
phate, pH 5 or 7, in the presence or absence of 3 mM ATP and
0.01 lM baﬁlomycin A1. Fractions were then incubated at 37 C for
2–60 min, after which reducing Laemmli sample buﬀer was added.
Samples were heated at 65 C for 15 min and then subjected to
SDS–PAGE followed by Western-blotting to determine the content
of the precursor and mature species of cathepsin B.2.5. Immunoblot analysis
Electrophoresed samples were transferred onto nitrocellulose mem-
branes for 60 min at 380 mA in transfer buﬀer containing 25 mM Tris
base and 192 mM glycine. The membranes were blocked by a 3 h incu-
bation with 5% skim milk in 10 mM Tris–HCl pH 7.5, 300 mM NaCl
and 0.05% Tween-20. The membranes were then incubated with the
primary antibody [sheep IgG against human cathepsin B PC049 (di-
luted 1:100), rabbit polyclonal antisera against rat procathepsin B
7183 (diluted 1:250) or rat cathepsin B propeptide 1149 (diluted
1:250)] in the above buﬀer for 16 h at 4 C. The blots were then washed
3 times with 0.5% skim milk in 10 mM Tris–HCl pH 7.5, 300 mM
NaCl and 0.05% Tween-20 over a period of 1 h at room temperature.
The bound immunoglobulin was detected using HRP-conjugated goat
anti-rabbit IgG.2.6. In vitro proteolysis of IGF-I by hepatic endosomes and cathepsin B
ENs (1 lg) was incubated for varying lengths of time at 37 C with
10–30 lg native IGF-I in 150 ll of 30 mM citrate–phosphate buﬀer
(pH 4–7) in the presence or absence of protease inhibitors. To deter-
mine the integrity of IGF-I, the ENs samples were acidiﬁed with acetic
acid (15%) and immediately loaded onto a RP-HPLC column.
For some experiments, native IGF-I was digested in vitro with bo-
vine cathepsin B. IGF-I (10 lg) was incubated with cathepsin B
(0.2 U) in 30 ll of 33 mM citrate–phosphate buﬀer, pH 4–7, for 2–
15 min at 37 C. The proteolytic reaction was stopped by addition of
reducing Tricine sample buﬀer and the samples were resolved on
16.5% Tris–Tricine gels according to the method of Schaﬀer & von Ja-
gow [16]. Bands were revealed by Coomassie Brilliant Blue staining of
the gels.
For the in vitro degradation of [125I]IGF-I by ENs, radiolabeled
IGF-I (13000 cpm) was incubated with ENs (1 lg) and various
concentrations of native IGF-I, human insulin or EGF in 50 mM
citrate–phosphate buﬀer, pH 5, for 30 min at 37 C. The amount
of degraded [125I]IGF-I was assayed by precipitation with 2 ml of
ice-cold TCA (10%) for 2 h at 4 C. The samples were then centri-
fuged at 10000 · g for 20 min at 4 C, and the supernatants and pel-
lets evaluated for their radioactive content using a Packard
c-counter.2.7. Immunodepletion studies
ENs was immunodepleted of active cathepsin B, cathepsin D,
cathepsin L or insulin-degrading enzyme prior to the digestion step
by incubating ENs (0.25 mg/ml) with antibodies precoated onto pro-
tein G-Sepharose beads for 16 h at 4 C in 600 ll of 20 mM sodium
phosphate buﬀer (pH 7). The fractions were then centrifuged for
5 min at 10000 · g, and the resultant immunodepleted supernatants
were used in the peptide degradation assay. The reaction was termi-
nated by the addition of 15% acetic acid and immediately analyzed
by RP-HPLC.
F. Authier et al. / FEBS Letters 579 (2005) 4309–4316 43112.8. HPLC separation of IGF-I peptides
RP-HPLC was performed using a Beckman Coulter System Gold
model 127 liquid chromatograph equipped with a Rheodyne sample
injector ﬁtted with a 0.5 ml loop and a lBondapak C18 column
(Waters, 0.39 · 30 cm; 10 lm particle size). Samples were chromato-
graphed using a mixture of 0.1% TFA in water (solvent A) and 0.1%
TFA in acetonitrile (solvent B) with a ﬂow rate of 1 ml/min. Elution
was carried out using three sequential linear gradients of 0–5% solvent
B (10 min), 5–15% solvent B (5 min) and 15–39% solvent B (32 min),
followed by an isocratic elution of 39% solvent B (20 min). Eluates
were monitored on-line for absorbance at 214 nm with a LC-166 spec-
trophotometer (Beckman Coulter).2.9. Mass spectrometry
Samples were prepared and analyzed using ion spray mass spectrom-
etry and HPLC-electrospray ionization mass spectrometry coupling as
previously described [6,7].Fig. 1. Assessment of IGF-I proteolysis by hepatic endosomes. Panels A–C
native IGF-I at 37 C for 15 min (panels A and B) or 15–90 min (panel C) in 3
in the absence or presence of 5 lg/ml pepstatin-A (PA), 1% Me2SO (DMSO),
0.1 mM 1,10-phenanthroline. At the end of the incubation, the proteolytic rea
were analyzed by RP-HPLC. Panel A, representative absorbance proﬁles at 2
the absence or presence of 0.1 lM CA074. The major degradation product
indicated and subjected to mass spectrometry analyses (see Table 1). Intac
hydrolysis of IGF-I was determined by following the disappearance of the pea
the amount of peptide degraded (% of control) (panel C) and normalized
Competition of native IGF-I, human insulin (HI) and EGF for the degradatio
37 C and pH 5 with the indicated concentrations of unlabeled peptides
precipitation with TCA. The percentage of [125I]IGF-I degraded in the absenc
three separate experiments and are expressed as a percentage of degradation3. Results
3.1. Catalytic properties of endosomal IGF-I-degrading activity
IGF-I proteolysis has previously been demonstrated in iso-
lated liver parenchymal endosomal fractions following addi-
tion of exogenous IGF-I [5]. Therefore, rat hepatic
endosomes were used in the present study to characterize
the proteolytic activity responsible for the endosomal degra-
dation of internalized IGF-I. A soluble endosomal fraction
(ENs) was ﬁrst assessed for its ability to proteolyze native
IGF-I in vitro (Fig. 1A–C). Fig. 1A shows the RP-HPLC
elution proﬁle of native IGF-I peptide alone (HPLC proﬁle
IGF-I), and a mixture of IGF-I and ENs incubated for
15 min at pH 5 (HPLC proﬁle IGF-I+ENs). Major inter-
mediate peptide peaks were observed in addition to the, Soluble endosomal fraction (ENs, 1 lg) was incubated with 10 lg
0 mM citrate–phosphate buﬀer pH 5 (panels A and B) or 4–7 (panel C)
1 mM PMSF, 1% MetOH, 1 lM E64, 0.1 lMCA074, 1 mM EDTA or
ction was stopped with acetic acid (15%), and the incubation mixtures
14 nm obtained following the incubation of native IGF-I with ENs in
s, pools 1–4, were collected from the elution proﬁle IGF-I + ENs as
t IGF-I had an elution time of 42 min. Panels B and C, The rate of
k area corresponding to the parent peptide. The results are expressed as
to that seen in the absence of added compound (panel B). Panel D,
n of [125I]IGF-I by ENs. ENs (1 lg) was incubated with [125I]IGF-I at
. The amount of degraded radiolabeled IGF-I was determined by
e of unlabeled peptide was 32% ± 5.2. Results are the means ± S.D. of
observed in the absence of added unlabeled peptides.
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peak height. The eﬀect of various protease inhibitors on the
acidic IGF-I-degrading activity was next examined (Fig. 1A
and B). The proteolytic activity observed at pH 5 was inhib-
ited by the cysteine-protease inhibitor E64 and a rapid inac-
tivator of cathepsin B, CA074 (Fig. 1A (HPLC proﬁle IGF-
I + ENs + CA074); Fig. 1B) [14]. No signiﬁcant eﬀect was
observed using serine, metallo- or aspartic acid protease
inhibitors. ENs was also examined for its ability to degrade
native IGF-I at various pH (pH 4–7) (Fig. 1C). Degradation
of IGF-I was pH dependent with maximal degradation ob-
tained at pH 5. A lower but signiﬁcant rate of hydrolysis
of IGF-I was observed at pH 4, 6 and 7.
Substrates of the same protease would be expected to com-
pete with each other for the enzyme binding site. We therefore
used a competition assay to evaluate the ability of native IGF-
I, HI and EGF to inhibit degradation of the radiolabeled sub-
strate [125I]IGF-I at pH 5 by ENs (Fig. 1D). The cathepsin B
substrate EGF [10] was found to inhibit [125I]IGF-I proteolysis
by ENs in a dose-dependent manner with a IC50 of 0.5 lM.
Native IGF-I was 3 times less eﬀective than EGF at compet-
ing for proteolysis of radiolabeled IGF-I (IC50 of 1.5 lM). HI,
a well-deﬁned cathepsin D substrate [7], was found to be less
potent than EGF and IGF-I.3.2. Sites of cleavage of IGF-I intermediates
Each of the major HPLC peaks (see Fig. 1A; HPLC
proﬁle IGF-I+ENs) was analyzed using mass spectrometry
to determine the molecular mass of the peptide products.
Table 1 lists the HPLC peaks, their retention times, theoret-
ical and experimental molecular masses, and structures.
After a 15 min incubation at neutral pH, only HPLC pool
1 can be detected. It contained intact IGF-I (7648 Da).
After a 15 min incubation at pH 5, three additional peaks
were observed (HPLC pools 2–4). HPLC pool 1 contained
both intact IGF-I and truncated IGF-I with the C-terminal
dipeptide Ser69-Ala70 clipped oﬀ. HPLC peaks 2, 3 and 4
correlated with the sequential removal of the N-terminal
Lys68, Ala67 and Pro66. The Gly1-Pro66 and Gly1-Lys65 were
not detected after a 15 min incubation at pH 4.Table 1
Masses and assigned structures of the cleavage products generated from nat
HPLC pools Retention time (min) Theoretical calculati
IGF-I + ENs/pH7
1 42 7648.7
IGF-I + ENs/pH5
1 42 7648.7
1 42 7490.5
2 40 7362.3
3 34 7291.3
4 14 7194.2
IGF-I + ENs/pH4
1 42 7648.7
1 42 7490.5
2 40 7362.3
Selected HPLC pools (see Fig. 1A, HPLC proﬁle IGF-I + ENs) generated
analyzed by RP-HPLC coupled with electrospray ionization-mass spectrom
pool 1 generated at pH 4 and 5 is heterogeneous. HPLC pool 1 contains in3.3. Identiﬁcation of endosomal IGF-I-degrading enzyme as
cathepsin B
The inhibition of IGF-I-degrading activity by E64 and
CA074, its aﬃnity binding to EGF, its low pH optimum and
its presence in the endosomal lumen as a soluble form sug-
gested cathepsin B as a likely candidate for this activity. We
therefore used well characterized polyclonal antibodies to ma-
ture cathepsin B and its proform [9] to deplete cathepsin B
from ENs (Fig. 2A and B). Quantitative immunoprecipitation
of cathepsin B using antibody directed against the rat enzyme
(7183) removed greater than 75% of the endosomal proteolytic
activity directed towards IGF-I as assessed by RP-HPLC.
Immunodepletion of ENs with antibodies to IDE [11], cathep-
sin D [7] or cathepsin L [9] failed to remove the proteolytic
activity (Fig. 2A and B).
To strengthen the physiological relevance of our observa-
tions obtained using cell-free endosomes, we compared the rate
of hydrolysis of IGF-I using pure cathepsin B at various pH,
followed by reducing Tris–Tricine gel and Coomassie Blue
staining (Fig. 2C). Optimal proteolytic conversion of native
IGF-I into IGF-I-intermediates (experimental molecular
masses ranging from 6- to 3.5-kDa) was observed at pH 5
and 6 with a cathepsin B concentration of 6.7 U/ml. IGF-1
degradation products were less abundant at pH 4 and 7.
To determine whether endosome acidity alters a processing
state of both the latent and mature forms of the cathepsin B en-
zyme within endocytic vesicles, we developed a method for
assaying procathepsin B processing in intact endosomes
(Fig. 2D). Freshly prepared endosomes were incubated at
37 C for various times at pH 5 or 7 in an isotonic buﬀer which
mimicked the intracellular milieu. At zero time, immunoblot
analyses using antibodies directed against mature cathepsin B
and its proform (antibody 7183) or rat cathepsin B propeptide
(antibody 1149) showed intense immunoreactivity for the 45-
kDa cathepsin B proenzyme (antibodies 7183 and 1149) and
low but detectable levels of the 32- and 28-kDa forms of active
cathepsin B (antibody 7183). Rapid conversion of the proen-
zyme to both active forms was evident by 2 min of incubation
of cell-free endosomes at pH 5 or 7 in the presence of ATP,
the substrate of the endosomal ATPase proton pump. No
digestion of the proenzyme occurred when hepatic endosomesive IGF-I by endosomal acidic IGF-I-degrading activity
on (Da) Mass analysis (Da) Assigned structure
7648 Gly1-Ala70
7648 Gly1-Ala70
7490 Gly1-Lys68
7363 Gly1-Ala67
7291 Gly1-Pro66
7194 Gly1-Lys65
7648 Gly1-Ala70
7490 Gly1-Lys68
7364 Gly1-Ala67
at pH 4, 5 and 7 by endosomal acidic IGF-I-degrading activity were
etry. Average molecular masses were used for the calculations. HPLC
tact IGF-I. Recovery of Gly1-Lys65 peptide (HPLC pool 4) was low.
Fig. 2. Identiﬁcation of endosomal IGF-I-degrading enzyme as cathepsin B. Panel A, ENs fractions were immunodepleted of active insulin-
degrading enzyme (IDE), cathepsin B (CB), cathepsin D (CD) or cathepsin L (CL) using their respective antibodies which had been precoated onto
protein G-Sepharose beads. Following centrifugation, the resultant supernatants were incubated with 10 lg native IGF-I in citrate–phosphate buﬀer
pH 5 at 37 C, and then analyzed by RP-HPLC. The rate of IGF-I proteolysis was determined by following the disappearance of the peak area
corresponding to the parent peptides. Panel B, Representative absorbance proﬁles at 214 nm obtained following the incubation of native IGF-I with
ENs fractions immunodepleted of active cathepsin B (a-CB supernatant) or CD (a-cathepsin D supernatant). Panel C, IGF-I (10 lg) was incubated
with cathepsin B (0.2 U) at 37 C in citrate–phosphate buﬀer pH 4–7 for the indicated times. The incubation mixtures were then analyzed by reducing
Tris–Tricine gel followed by Coomassie Brilliant Blue Staining. Molecular mass markers are indicated to the left of the panel. Arrow on the right
indicates the mobility of intact IGF-I (7.6-kDa). Panel D, EN fractions were isolated from control rats and incubated in isotonic buﬀer at 37 C and
pH 5 or 7 in the presence or absence of 3 mM ATP or 3 mM ATP + 0.01 lM baﬁlomycin A1. After various incubation times, the samples were
evaluated for their content of procathepsin B and mature cathepsin B by immunoblotting with the indicated polyclonal antisera. Bands on the blot
were visualized by ECL. Arrows indicate the mobility of procathepsin B (45-kDa) and mature cathepsin B (32- and 28-kDa).
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baﬁlomycin A1, a speciﬁc inhibitor of the vacuolar H+-ATPase.
3.4. IGF-I internalization and degradation in human hepatoma
cells
To strengthen the physiological relevance of our observa-
tions obtained with cell-free endosomes, we studied the meta-
bolic fate of [125I]IGF-I internalized in intact HepG2 cells
(Fig. 3). This human hepatoma cell line expresses detectable
levels of IGF-I and IGF-I/insulin hybrid receptors [17,18].
Based on the acid-wash procedure, time-course studies of
IGF-I internalization yielded a t1/2 value of 10 min
(Fig. 3A). Steady state was reached by 45 min (Fig. 3A)
and represented 34% of the total cell-associated [125I]IGF-I.
The proportion of internalized [125I]IGF-I that was TCA-solu-
ble increased with time, representing 24% at 60 min. Treat-
ment of HepG2 cells with the cathepsin B proinhibitor
CA074-Me caused a 4–6-fold decrease in the intracellular pro-
teolysis of IGF-I (Fig. 3A). These data suggest that cathepsin
B, whose presence in HepG2 cell-lysates was conﬁrmed by
Western-blotting (see Fig. 3B), is responsible for most recep-
tor-mediated [125I]IGF-I degradation in vivo.
IGF-I proteolysis was also investigated using lysates from
control and CA074Me-treated HepG2 cells which were incu-bated with exogenous [125I]IGF-I at pH 5 (Fig. 3C). Tris–Tri-
cine gel analysis revealed that [125I]IGF-I proteolysis was rapid
using lysates isolated from control cells (>90% degradation
after a 20 min incubation), whereas the proteolysis of radiola-
beled IGF-I was clearly reduced using lysates from cells treated
with CA074-Me (Fig. 3C).4. Discussion
In this study, the soluble cysteine protease cathepsin B has
been identiﬁed as the IGF-I-degrading activity responsible
for the primary cleavages of internalized IGF-I within endo-
somes. Using similar approaches, we have previously reported
that hepatic endosomes contain active cathepsin B that pro-
cesses internalized glucagon [9] and EGF [10]. Recently, we
have also shown that cysteine proteinase inhibitors prevented
the endosomal processing of internalized IGF-I in MCF-7
and H-59 tumor cells [5]. Using highly puriﬁed hepatic
endosomes, we have demonstrated in this present work that
the endosomal IGF-I-degrading enzyme and cathepsin B are
identical, as indicated by the following observations: (a) the
optimum pH and inhibitor proﬁle of the endosomal
proteolytic activity were similar to those of cathepsin B; (b)
Fig. 3. IGF-I internalization and degradation in human HepG2 hepatoma cells. Panel A, HepG2 cells were treated with or without 1 lMCA074-Me
for 1 h prior to the addition of [125I]IGF-I. At the indicated times, cells were placed on ice, acid washed and lysed in 6% TCA. The acid washes, non-
acid extractable TCA-soluble and -precipitable radioactivity were counted in a c-counter. Results are the means ± S.D. of two experiments
performed in duplicate wells. Panel B, HepG2 cell lysate was subjected to reducing SDS–PAGE, transferred to nitrocellulose and immunoblotted
with sheep anti-human cathepsin B PC049. Panel C, HepG2 cells were treated for 1 h with or without 1 lMCA074-Me. The cells were lysed, and the
clariﬁed cell lysates were incubated at 37 C and pH 5 with [125I]IGF-I for the indicated times. The integrity of [125I]IGF-I was then analyzed on a
reducing Tris–Tricine gel followed by autoradiography. Results represent two diﬀerent experiments. Molecular mass markers are indicated to the left
of the panel. Arrow on the right indicates the mobility of intact IGF-I (7.6-kDa).
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to a loss of IGF-I-degrading activity; (c) endosomal IGF-I-
degrading activity and pure cathepsin B produced cleavage
patterns for IGF-I that were in accordance with the carboxy-
peptidase activity of cathepsin B; (d) IGF-I and the high-aﬃn-
ity cathepsin B substrate EGF displayed comparable IC50
values; and (e) Western-blot experiments demonstrated the
presence of the 32- and 28-kDa active forms of cathepsin B
in the endosomal lumen, as well as its 45-kDa inactive precur-
sor which was processed to the active forms under ATP-depen-
dent endosomal acidiﬁcation conditions.
In addition, using human HepG2 hepatoma cells, we pro-
vide evidence that internalized [125I]IGF-I is a physiological
substrate for the intracellular cathepsin B protease. A rapid
internalization of [125I]IGF-I has previously been demon-
strated in CHO cells stably transfected with the human IGF-I
receptor [4], in Rat-1 ﬁbroblasts [15] and in human osteosar-
coma MG-63 cells [3]. In these studies [3,15], the internaliza-
tion of [125I]IGF-I reached a maximum at 1 h and slowly
declined thereafter. Moreover, a progressive degradation of
internalized [125I]IGF-I was demonstrated up to 2 h of incuba-
tion and was inhibited by the addition of lysosomotropic
agents or leupeptin [3]. Our present work extends these obser-
vations to human HepG2 cells which express IGF-I and IGF-
I/insulin hybrid receptors [17,18], and indicates that cathepsinB is mainly responsible for the intracellular degradation of
internalized [125I]IGF-I. However, the cathepsin B proinhibi-
tor CA074-Me did not completely inhibit [125I]IGF-I proteol-
ysis either in vivo in HepG2 cells or in vitro using HepG2
cell lysates, suggesting the potential minor contribution of an-
other endosomal or lysosomal protease to the processing of
radioactive IGF-I.
Originally, it was believed that the active forms of cathepsin
B resided solely in lysosomes, leading to the proposal that acti-
vation occurred in the same compartment [19]. Recent reports
demonstrated that both precursor and mature cathepsin B
were also present in the endosomal compartment [9,10] sug-
gesting that proteolytic activation may occur in the endosomal
apparatus, as already demonstrated for the maturation of the
precursor of the aspartic proteinase cathepsin D [20]. Proca-
thepsin B contains a highly accessible region, close to the
NH2 terminus of the mature enzyme, which is very susceptible
to proteolytic attack by several endosomal proteinases [19].
Our studies with intact cell-free endosomes support this
hypothesis and show that ATP-dependent endosomal acidiﬁ-
cation is required for proenzyme activation. It still remains
to be determined whether maturation of endosomal procathep-
sin B occurs by an unimolecular autoprocessing event [21] or
intermolecular processing by endosomal cathepsin B or other
endosomal cathepsins [22,23].
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ing that 20–40% of newly synthesized lysosomal hydrolases
can be detected in early endosomes [24]. In hepatic endosomes,
cathepsin B processes internalized glucagon, EGF and EGF
receptor at acidic pH [9,10]. In macrophage endosomes,
cathepsin B is responsible for proteolytic cleavage of ricin A
chain at both neutral and acidic pH [25]. In pancreatic b-cells,
a pool of endosomal procathepsin B was identiﬁed [26] and, in
thyroid epithelial cells, procathepsin B is ﬁrst transported to
compartments of the late endocytic pathway where it matures
before being secreted [27]. Finally, in Vero cells, cathepsin B is
responsible for the endosomal proteolysis of the Ebola virus
glycoprotein-1 [28].
According to the sequences of the peptide products, the
main proteolytic activity participating in the endosomal degra-
dation of IGF-I at acidic pH can be attributed to a carboxy-
peptidase activity that generates four major IGF-I
metabolites: Gly1-Lys68, Gly1-Ala67, Gly1-Pro66 and Gly1-
Lys65. Thus, the pattern of IGF-I peptides produced within
endosomes is in accordance with the dipeptidyl carboxypepti-
dase activity of cathepsin B observed at acidic pH [22]. The
resistance of Gly1-Lys65 to digestion by cathepsin B and/or
other endosomal proteases, even after a long digestion time,
may result from inaccessibility of the enzyme(s) to the cleavage
sites. Using a similar approach, we found C-terminally trun-
cated forms of EGF [10] and glucagon [9] produced by endo-
somal cathepsin B.
The cathepsin B cleavage sites within IGF-I are located at
the carboxyl terminus of the D-domain of the peptide which
contains eight amino acids [2]. Studies on the structural
requirements for IGF-I/IGF-I receptor binding have shown
that the removal of the D-region of hIGF-I has little eﬀect
on binding to the type-1 IGF receptor [29]. Moreover, [1-
62]hIGF-I displays a 2-fold higher aﬃnity for the insulin
receptor and a 4-fold higher aﬃnity for IGF serum-binding
proteins. Thus, as previously demonstrated for PTH-(1-84)
[30], glucagon [31] and endocytosed protein antigens for major
histocompatibility class II presentation [32], changes in the
biological activity of the IGF-I peptide were observed follow-
ing processing in endosomes.
We have shown that binding and cleavage of IGF-I (this
study; [6]) and EGF [6,10] were not due to the endosomal insu-
linase cathepsinD.Moreover, we have previously demonstrated
that the aromatic locus PheB24-PheB25-TyrB26 of the insulin B
chain and the corresponding Phe24-Phe25-Tyr26 bonds in the
insulin moiety of proinsulin dictate insulin and proinsulin bind-
ing to and degradation by endosomal cathepsin D [7,33]. The
diﬀerences in primary sequence between positions Phe-Phe-
Tyr of the insulin and proinsulin peptides and the corresponding
positions Phe-Tyr-Phe of IGF-I might explain the lack of bind-
ing and cleavage of the IGF-I peptide by cathepsin Dwhich dis-
plays a high selectivity for the Phe-Phe bond [34]. Another
contributing factor may be the steric interference caused by
the presence of D-chain residues in IGF-I but not in insulin
and proinsulin [29]. Thus, since the eight amino acidD-chain re-
gion of IGF-I may interfere with binding to the 23–25 region [2],
any protein that interacts with the B24-B26 region of insulin will
exhibit lower aﬃnity for IGF-I.
A connecting peptide links the carboxyl terminus of the B-
region to the amino terminus of the A-region in the proinsulin
(35 amino acid C-peptide) and IGF-I (12 amino acid C-do-
main) polypeptides [2]. Whereas proinsulin was cleaved ateight bonds within the C-peptide by endosomal cathepsin D
[33], we did not observe any cleavage in the connecting C-do-
main of IGF-I. Our inability to show cleavage of IGF-I in the
Gly30-Thr41 peptide despite the presence of cathepsin D in our
endosomal fractions [7] may be explained by the major diﬀer-
ences observed in the length and amino acid composition of
the proinsulin and IGF-I connecting peptides.
A previous report has shown that cathepsin D can eﬃciently
proteolyze IGF-I and -II as well as IGFBP-1 to -5 in vitro at
pH 4 in a time and concentration-dependent manner [35]. This
contrasting report may have reﬂected the very low pH (pH 4)
and/or the extremely high enzyme/substrate ratio (1 lg
cathepsin D per assay) and time of incubation (6–20 h) used
in their digestion assay. Moreover, in these studies, the nature
of the alterations of IGF-I was based on comparison of the
electrophoretic mobility of intact radioactive IGF-I to that
of cathepsin D-digested radiolabeled peptide. Thus, radioac-
tive IGF-I might not display all the structural elements of
the natural peptide substrate and the radioactive iodine on
the molecule might alter the enzyme-substrate recognition.
Whatever the physiological relevance of these studies, our
work identiﬁes an IGF-I-degrading enzyme in endosomes
which is distinct from cathepsin D and functional at the endo-
somal pH (pH 5.5–7).
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